Fujirebio and Sysmex to Collaborate On Development of Unique Immunoassays

Sysmex has been a key player in the field of in vitro diagnostics for over half a century, establishing both a solid technological base and an expansive global network. The company is keen to accelerate its presence in the immunochemistry sector, especially in the U.S. and European markets. Sysmex has been actively working on introducing unique, value-added tests, including the development of reagents that can detect the buildup of amyloid beta (Aβ) in the brain from blood samples, a key factor in Alzheimer's disease, in both Japanese and U.S. laboratory developed test (LDT) markets.

Fujirebio, on the other hand, boasts a comprehensive portfolio of reagent raw materials due to its long history in the immunoassay field. Lately, the company has not only been focused on developing its own products but has also been strengthening its Contract Development and Manufacturing Organization (CDMO) strategy to promote the global roll-out of specialized tests. Since 2020, Fujirebio has been collaborating with Sysmex by creating specialized reagents for Sysmex's Automated Immunoassay System, known as HISCL-Series, through its subsidiary companies.

Both Fujirebio and Sysmex have agreed to further deepen their cooperative efforts. This decision is based on a mutual understanding that pooling their individual expertise in the immunoassay field can help them both expand globally and foster advances in this scientific area. The companies plan to identify specific areas where they can collaborate more deeply—like research, manufacturing, clinical trials, and sales strategies—with the goal of moving to the implementation stage by the end of March 2024. Fujirebio and Sysmex are committed to offering high-value tests to their global customer base as early as possible, driven by the strengthening of their partnership in immunoassay.

Related Links:
Fujirebio Holdings 
Sysmex Corporation